Aim: Variations in tumour biology and outcomes depending upon PTL have been reported in aCRC. We tested effects of PTL in two phase III randomised trials. Results: PTL was RC in 575 (28%), LC in 801 (39%) and rectum in 699 (34%) pts. RC tumours had more BRAF mutations (n = 1136, 22% vs 6%, p < 0.001), lower EREG/ AREG expression (n = 323, p < 0.001) and a higher rate of dMMR (n = 688, p < 0.001). In prognostic analysis, RC was associated with worse 1 st -line PFS (HR = 1.23, p = 0.05) and OS (HR = 1.44, p < 0.001), independent of BRAF status, but it was not significantly prognostic in 2 nd -line. In predictive analysis, no PTL/ treatment interactions were seen, with raw data (table) or after adjustment for prognostic factors including BRAF. Conclusions: We confirm that RC tumours are biologically distinct, and have worse outcomes with 1 st -line therapy. We did not find PTL to be predictive for the benefit of the drugs under test in these trials, so cannot recommend its use for selection of therapy. Better objective predictive biomarkers are required. Disclosure: All authors have declared no conflicts of interest.
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